| Overview |
| bs-11087r-pe-100ul |
| LRFN2/SALM1 Polyclonal Antibody, PE Conjugated |
| WB |
| Rat |
| Human, Mouse, Dog, Cow, Sheep, Pig, Horse, Chicken, Rabbit |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LRFN2/SALM1 |
| 401-500/789 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| leucine rich repeat and fibronectin type III domain containing 2; RP11-535K1.2; fibronectin type III, immunoglobulin and leucine rich repeat domains 2 antibody FIGLER2; Leucine-rich repeat and fibronectin type-III domain-containing protein 2; LRFN2; LRFN2_HUMAN; SALM1; Synaptic adhesion-like molecule 1. |
| LRFN2 is a 789 amino acid single-pass type I membrane protein belonging to the LRFN family. Encoded by a gene that maps to human chromosome 6p21.2, LRFN2 is moderately expressed in brain, spleen and testis. LRFN2 contains one fibronectin type-III domain, one Ig-like (immunoglobulin-like) domain and six LRR (leucine-rich) repeats. LRFN2 promotes neurite outgrowth in hippocampal neurons, enhances cell surface expression of two NMDA receptor subunits, NMDA1 and NMDA?1, and may play a role in redistributing PSD-95 to cell periphery. LRFN2 forms heteromeric complexes with LRFN1, LRFN3, LRFN4 and LRFN5, and is capable of forming homomeric complexes, but not across cell junctions. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz